Keno has over 25 years of Biotech experience spanning operations (CEO of Brandaris Therapeutics), investing (private and public equities at M Ventures and Omega Funds), investment banking (Piper Sandler), management consulting (IQVIA), and medical research (MRC).

Prior to joining BGV, Keno was as Managing Director and Vice President at M Ventures responsible for Biotech investments (Biopharma and Life Sciences).

Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College in London and an MBA from INSEAD. He is the inventor of a patent in the field of neurosciences and his research in lipid metabolism has been published in the top scientific journal Nature.